《盈警響號》諾誠健華-B(09969.HK)料上半年虧損擴至最多4.95億人幣
諾誠健華-B(09969.HK)公布,預期截至6月底止中期的綜合收入不少於2.36億元人民幣(下同),按年增長不少於132.2%,主要是由於奧布替尼的銷售增加。
期內,公司料綜合淨虧損不超過約4.95億元,較去年同期綜合淨虧損約2.094億元擴大不超過136.4%,主要由於集團的研發成本因其進入臨床試驗階段的產品以及開展臨床試驗數量的明顯增加而大幅增加;匯兌損失淨額上升,其主要原因是公司採用美元為記賬本位幣,而集團日常經營活動主要在內地,公司股份於香港上市及增發的所得款項主要被兌換為離岸人民幣,故集團以非記賬本位幣人民幣計值的現金及銀行結餘金額相對較高,而由於上半年人民幣對美元匯率波動因素影響,使得在會計處理方面,2022年上半年預計產生的未實現匯兌損失金額明顯增加。
此外,公司擬在上交所科創板發行不逾2.65億股A股,保薦人為中金公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.